What is the preferred treatment between Prolia (denosumab) and Jubbonti for a patient with established osteoporosis and high risk of fracture?

Prolia vs. Jubbonti for Osteoporosis Treatment

For patients with established osteoporosis at high risk of fracture, Prolia (denosumab) is the preferred treatment over Jubbonti (romosozumab), based on FDA approval, established fracture reduction efficacy, and superior safety profile. 1

Treatment Selection Algorithm

First-Line Therapy: Prolia (Denosumab)

Prolia should be selected as first-line therapy for most patients with established osteoporosis at high fracture risk because it has:

• FDA approval specifically for postmenopausal osteoporosis at high fracture risk, with proven reduction in vertebral, nonvertebral, and hip fractures 1
• Demonstrated fracture reduction in the pivotal FREEDOM trial, maintained over 10 years of treatment 2
• Superior BMD improvements compared to bisphosphonates, including in patients switched from bisphosphonate therapy 3, 4
• Convenient dosing of subcutaneous injection every 6 months, which improves adherence 3

When to Consider Jubbonti (Romosozumab) Instead

Romosozumab should be reserved for very high-risk patients only, specifically those with: 5

• Prior osteoporotic fracture(s) AND
• BMD T-score ≤ -3.5 OR
• FRAX 10-year risk of major osteoporotic fracture ≥30% or hip fracture ≥4.5% OR
• High-dose glucocorticoid use (≥30 mg/day for >30 days or cumulative ≥5 g/year) 5

The 2022 American College of Rheumatology guidelines conditionally recommend anabolic agents (including romosozumab) over antiresorptive agents only in patients meeting very high fracture risk criteria 5

Critical Safety Considerations

Romosozumab (Jubbonti) Safety Concerns

The ACR conditionally recommends against romosozumab except in patients intolerant of other agents due to: 5

• Uncertain cardiovascular harms including increased myocardial infarction, stroke, and death 5
• Limited duration of use (12 months maximum)
• Mandatory transition to antiresorptive therapy required after completion 5

Denosumab (Prolia) Safety Profile

Prolia is generally well-tolerated with: 2, 6, 7

• Favorable safety profile maintained over 10 years of treatment 2
• Overall adverse event rates similar to placebo in clinical trials 7
• Primary concern: rebound vertebral fractures after discontinuation, requiring sequential therapy planning 8, 2

Essential Pre-Treatment Requirements

For Patients with Advanced Kidney Disease (eGFR <30 mL/min)

Before initiating Prolia in patients with advanced chronic kidney disease, you must: 1

• Evaluate for chronic kidney disease-mineral bone disorder (CKD-MBD) with intact PTH, serum calcium, 25(OH) vitamin D, and 1,25(OH)₂ vitamin D
• Ensure supervision by a provider with CKD-MBD expertise, as severe hypocalcemia resulting in hospitalization and fatal cases have been reported 1

For All Patients

Prior to initiating either medication: 1

• Rule out pregnancy in all females of reproductive potential (both medications can cause fetal harm) 1
• Ensure adequate calcium (1,000-1,200 mg daily) and vitamin D (600-800 IU daily) supplementation 8, 9

Treatment Duration and Sequential Therapy

Prolia Treatment Protocol

• Initial therapy duration: 5 years 8
• After 5 years, reassess fracture risk to determine if continued therapy is warranted 8
• If discontinuing, transition to bisphosphonate to prevent rebound bone loss and vertebral fractures 8

Romosozumab Treatment Protocol

• Maximum duration: 12 months 9
• Mandatory immediate transition to bisphosphonate or denosumab after completion to maintain bone gains 9

Common Clinical Pitfall

The most critical error is discontinuing denosumab without sequential therapy. Discontinuation leads to increased risk of multiple vertebral fractures due to rebound bone turnover 8, 2. Always plan for transition to bisphosphonate therapy before stopping denosumab.

Practical Recommendation

For the typical patient with established osteoporosis at high fracture risk, start with Prolia (denosumab) 60 mg subcutaneously every 6 months. 1 Reserve romosozumab for the subset of patients meeting very high-risk criteria who can tolerate the cardiovascular risk profile and commit to mandatory sequential therapy after 12 months. 5, 9